HER2 and ABCC1 are identified as significant transcriptomic predictors of overall survival in patients treated with T-DXd. A large-scale analysis reveals novel predictors of survival and resistance ...
Researchers have revealed how patients with metastatic breast cancer develop resistance to Enhertu treatment.
Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ...
BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populationsNo Bria-IMT ...
BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard ...
Greenwich's $3.81 million cash position covers less than two months of operations, making near-term financing highly likely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results